Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KK2845
- Development stage
- Unknown
- Lead developer
- Kyowa Kirin
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KK2845 is an antibody-drug conjugate (ADC) developed by Kyowa Kirin targeting T-cell immunoglobulin mucin-3 (TIM-3). It is designed to treat hematologic malignancies, specifically acute myeloid leukemia (AML), by targeting TIM-3 expressed on leukemic stem cells and blasts. The molecule consists of a non-fucosylated fully human anti-TIM-3 IgG1 monoclonal antibody, which is engineered for enhanced antibody-dependent cellular cytotoxicity (ADCC), conjugated to a pyrrolobenzodiazepine (PBD) dimer payload (SG3249, also known as tesirine) via a valine-alanine linker. Upon binding to TIM-3 and internalization, the PBD payload is released, leading to DNA cross-linking and cell death. KK2845 is currently being evaluated in Phase I clinical trials for relapsed or refractory AML.
- Other names
- anti-TIM-3 ADCanti-TIM3 ADCanti-TIM 3 ADC
02
Targets
DNAHAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on KK2845.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KK2845.